SCHEMBL14920522

SCHEMBL14920522

O=C(O)N(C(=O)O)c1noc2ccc(-c3cc(Cl)ccc3O)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.40
KMT2A Q03164 6/20 0.39
MEN1 O00255 5/20 0.39
MAPT P10636 4/20 0.39
LMNA P02545 2/20 0.39
HPGD P15428 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
EPHX2 P34913 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
PIM1 P11309 1/20 0.36
SCN9A Q15858 1/20 0.36
IDO1 P14902 1/20 0.35
ALDH1A1 P00352 2/20 0.35
SLC9A1 P19634 1/20 0.34
ESR1 P03372 2/20 0.34
ESR2 Q92731 2/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14920445 0.85 MEN1 (0.39) KMT2AMEN1MAPTLMNAHPGD
SCHEMBL14920041 0.84 AMY1A (0.33) FAAHSCN9AESR1ESR2
SCHEMBL14933629 0.83 FAAH (0.42) FAAHKMT2AMEN1MAPTLMNA
SCHEMBL14920162 0.78 TP53 (0.41) FAAHKMT2AMEN1MAPTLMNA
SCHEMBL16021504 0.77 MEN1 (0.45) FAAHKMT2AMEN1MAPTLMNA
SCHEMBL14919892 0.77 SCN9A (0.45) KMT2AMEN1MAPTLMNAHPGD
SCHEMBL14920203 0.76 ESR1 (0.50) MAPTNPSR1ALDH1A1ESR1ESR2
SCHEMBL14920302 0.72 MEN1 (0.47) KMT2AMEN1MAPTLMNAHPGD
SCHEMBL14920351 0.72 PIM1 (0.41) MAPTHPGDALOX15MAPK1PIM1
SCHEMBL14920262 0.71 DHODH (0.45) CA1CA2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2773641-B1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2017-09-27 EP disclosed
US-9481677-B2 Biaryl ether sulfonamides and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2016-11-01 US disclosed
US-9365578-B2 2016-06-14 US disclosed
US-20140256736-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2014-09-11 US disclosed
EP-2773641-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2014-09-10 EP disclosed
WO-2013064984-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256736-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS TRPV1, TRPV3, TRPV2 FAAH 147/4885KMT2A 1370/4885MEN1 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.